

ID: Dr. Willemse  
 Sex: F  
 Birthdate: 10/12/1936

Exam Date: 7/15/2022  
 Exam Description: External Patient: OCT




# deepeye® TPS - nAMD Therapy Planning Support

short - term


Laterality: OD (R)

Prediction and Progression of Current Disease Activity:




**High**  
 Probably high  
 Probably low  
 Low

Interpretation: **High:** prediction of high disease activity (50-100%) | **Low:** prediction of low disease activity (49-0%)



Foveal B-Scan (49 of 97)




Foveal Segmented B-Scan (49 of 97)

IRF - Intraretinal Fluid  
 SRF - Subretinal Fluid  
 PED - Pigment Epithelial Detachment

long - term

Prediction and progression of Long-Term Treatment Need (next 12 months):



**High**  
 Probably high  
 Probably low  
 Low

Interpretation:

**High:** prediction to receive more than 6 anti-VEGF therapy injections (50-100%)  
**Low:** prediction to receive 6 or less anti-VEGF therapy injections (49-0%)

note


The AI analysis **does not replace the expert judgement of a qualified doctor**. Please observe the restrictions in the instructions for use ([www.deepeye-medical.com/eifu](http://www.deepeye-medical.com/eifu)) as well as the opinion of your local ophthalmological society for any treatment decision.  
 From the statement of the professional associations DOG, RG and BVA:  
 After initial therapy (upload), treatment strategy with intravitreal injections at least 4 weeks apart (brolucizumab at least 8 weeks):

- If there is high disease **activity**, treatment for PRN (pro re nata) or shortening of the interval by 2 to 4 weeks for T&E (treat & extend).
- If there is **no activity**, treatment can be suspended (PRN) or the interval can be extended by 2 to 4 weeks (T&E), provided that funduscopy and visual acuity do not contradict this.


AMD-Prog 2, SPEC IR+OCT AppWay

ID: Dr. Willemse  
 Sex: F  
 Birthdate: 10/12/1936



Exam Date: 7/15/2022  
 Exam Description: External Patient: OCT




B-Scan: 43 of 97




B-Scan with most SRF: 43 of 97



B-Scan: 40 of 97



B-Scan with most PED: 40 of 97



**Summary of the AI report** (this is **not a medical report**, just merely a summary of the AI results).

- The OCT of the patient shows **high** disease activity in the **right** eye on **15.07.2022**.
- Most subretinal fluid was seen in B-Scan **43** of 97. Highest PED in B-Scan **40**.
- The long-term prognosis shows a trend towards **high** disease activity.

For instructions for use please visit: [www.deepeye-medical.com/eifu](http://www.deepeye-medical.com/eifu)

**Notice:** In case of any incidents (in relation with the medical device), please contact the local competent authority and/or the manufacturer: [feedback@deepeye-medical.com](mailto:feedback@deepeye-medical.com).



(01) 4262449580017  
 (8012) v1.3.0



deepeye Medical GmbH  
 Paul-Heyse-Str. 2-4,  
 80366 Munich, Germany  
[www.deepeye-medical.com](http://www.deepeye-medical.com)

Job-ID 6877663aa3ae83994169278c  
 Date & time: 2025-07-16 10:44:50